News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Jonathan Ticku: I Had the Opportunity to Give Testimony to the FDA ODAC in Support of Daratumumab for High-Risk Smoldering Myeloma
Jonathan Ticku
May 26, 2025, 07:49

Jonathan Ticku: I Had the Opportunity to Give Testimony to the FDA ODAC in Support of Daratumumab for High-Risk Smoldering Myeloma

Jonathan Ticku, Assistant Professor of Oncology at Mayo Clinic and GU Oncology Lead at Mayo Clinic Health System, shared a post on LinkedIn:

“This week I had the opportunity to give testimony to the FDA Oncologic Drugs Advisory Committee (ODAC) in support of daratumumab for high risk smoldering myeloma.
I was able to represent the perspective and challenges of practicing community hematologists and oncologists.
The ODAC voted in favor (6:2) for daratumumab use in high-risk smoldering myeloma, based on the results of the AQUILA study.”

Jonathan Ticku: I Had the Opportunity to Give Testimony to the FDA ODAC in Support of Daratumumab for High-Risk Smoldering Myeloma

More posts featuring Jonathan Ticku

AQUILA Study cancer Daratumumab FDA Oncologic Drugs Advisory Committee Jonathan Ticku Myeloma OncoDaily Oncology
Special Coverage
Blog
Jul 10, 2025, 21:24
At AACR25, Douglas Hanahan Showed That IL-1 Family Signaling Drives Systemic Immunosuppression in HPV Cancers
Blog
Jul 10, 2025, 21:13
Raelyn Was Just 4 Years Old When She Was Diagnosed With T-Cell Acute Lymphoblastic Leukemia - St. Baldrick's Foundation
Blog
Jul 10, 2025, 20:58
Janna Sisakyan: I Am Excited to Carry These Lessons Forward in My Future Medical Career
Blog
Jul 10, 2025, 20:44
We’re Excited to Announce That the First Patient Has Been Randomised in the PROLoNG Study - EORTC
Blog
Jul 10, 2025, 20:32
Paolo Tarantino: Incredibly Excited to Co-Chair the NRG Oncology Summer Symposium 2025
Blog
Jul 10, 2025, 20:21
Joshua Brody: Crystal-Clear Update on Treating Aggressive Lymphomas
Insight
Jul 10, 2025, 20:08
Pashtoon Kasi: The 1st Agnostic Study of a PARP Inhibitor
Drugs
Jul 10, 2025, 16:59
Taletrectinib (Ibtrozi): What Patients Should Know About in 2025?
Blog
Jul 10, 2025, 16:30
Indiana’s First Mobile Lung Screening Unit Proves That Access to Care Saves Lives - IU Simon Comprehensive Cancer Center
Blog
Jul 10, 2025, 16:24
Herbert Loong: Had an Opportunity to Introduce and Discuss Soft Tissue Sarcomas at Radio Television Hong Kong
Blog
Jul 10, 2025, 16:14
Sebastian Other-Gee Pohl Completed 2 Years of EACR-Boehringer Ingelheim Postdoctoral Fellowship
Blog
Jul 10, 2025, 16:11
Heba Bakri: Honored to Welcome Assiut University Heamtology Team for a Discussion on Multiple Myeloma Management